Zobrazeno 1 - 10
of 290
pro vyhledávání: '"Douglas E Vaughan"'
Autor:
Nicolas Pelisch, Takashi Dan, Atsuhiko Ichimura, Hiroki Sekiguchi, Douglas E Vaughan, Charles van Ypersele de Strihou, Toshio Miyata
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0124510 (2015)
Multiple sclerosis (MS) is characterized by inflammatory demyelination and deposition of fibrinogen in the central nervous system (CNS). Elevated levels of a critical inhibitor of the mammalian fibrinolitic system, plasminogen activator inhibitor 1 (
Externí odkaz:
https://doaj.org/article/1a57e21a89df49eb9480bde40a663de0
Autor:
Marquitta J White, Nuri M Kodaman, Reed H Harder, Folkert W Asselbergs, Douglas E Vaughan, Nancy J Brown, Jason H Moore, Scott M Williams
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0136379 (2015)
Plasminogen activator inhibitor 1 (PAI-1), a major modulator of the fibrinolytic system, is an important factor in cardiovascular disease (CVD) susceptibility and severity. PAI-1 is highly heritable, but the few genes associated with it explain only
Externí odkaz:
https://doaj.org/article/123349fc3f1947578b342de75ff16a10
Autor:
Amanda E Boe, Mesut Eren, Luisa Morales-Nebreda, Sheila B Murphy, G R Scott Budinger, Gökhan M Mutlu, Toshio Miyata, Douglas E Vaughan
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0116504 (2015)
Nω-nitro-L-arginine methyl ester (L-NAME) treatment induces arteriosclerosis and vascular senescence. Here, we report that the systemic inhibition of nitric oxide (NO) production by L-NAME causes pulmonary emphysema. L-NAME-treated lungs exhibited b
Externí odkaz:
https://doaj.org/article/1b1a764187d84af89105945562e912f4
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e63825 (2013)
Fibrosis is defined as an abnormal matrix remodeling due to excessive synthesis and accumulation of extracellular matrix proteins in tissues during wound healing or in response to chemical, mechanical and immunological stresses. At present, there is
Externí odkaz:
https://doaj.org/article/d29c592e0271482db30c1bfa781558dc
Autor:
Nadia M Penrod, Kwabena A Poku, Douglas E Vaughan, Folkert W Asselbergs, Nancy J Brown, Jason H Moore, Scott M Williams
Publikováno v:
PLoS ONE, Vol 6, Iss 1, p e16639 (2011)
The proteins, tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1), act in concert to balance thrombus formation and degradation, thereby modulating the development of arterial thrombosis and excessive bleeding. PAI-1 is
Externí odkaz:
https://doaj.org/article/cf522aa473b64477851509059ad75c6b
Autor:
Douglas E. Vaughan
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 18 (2023)
Externí odkaz:
https://doaj.org/article/c52a7dc944644a96a8e5abe4c62a47dc
Autor:
Joshua A. Levine, Carlota Oleaga, Mesut Eren, Ansel P. Amaral, Meng Shang, Elizabeth Lux, Sadiya S. Khan, Sanjiv J. Shah, Yasuhiro Omura, Nathalie Pamir, Joshua Hay, Grant Barish, Toshio Miyata, Hagai Tavori, Sergio Fazio, Douglas E. Vaughan
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract Plasminogen activator inhibitor 1 (PAI-1) is a functional biomarker of the metabolic syndrome. Previous studies have demonstrated that PAI-1 is a mechanistic contributor to several elements of the syndrome, including obesity, hypertension an
Externí odkaz:
https://doaj.org/article/70f544abac804254b08f94ba760c8b5e
Autor:
Takashi Yahata, Abd Aziz Ibrahim, Ken-ichi Hirano, Yukari Muguruma, Kazuhito Naka, Katsuto Hozumi, Douglas E. Vaughan, Toshio Miyata, Kiyoshi Ando
Publikováno v:
Haematologica, Vol 106, Iss 2 (2020)
Therapeutic strategies that target leukemic stem cells (LSCs) provide potential advantages in the treatment of chronic myeloid leukemia (CML). Here, we show that selective blockade of plasminogen activator inhibitor-1 (PAI-1) enhances the susceptibil
Externí odkaz:
https://doaj.org/article/33be840ab0fa4143ad05bd208fc116c2
Autor:
Rahul Rai, Suresh K. Verma, David Kim, Veronica Ramirez, Elizabeth Lux, Chengjin Li, Susmita Sahoo, Lisa D. Wilsbacher, Douglas E. Vaughan, Susan E. Quaggin, Asish K. Ghosh
Publikováno v:
Epigenetics, Vol 12, Iss 11, Pp 1004-1013 (2017)
Hypertension-associated end-organ damage commonly leads to cardiac and renal fibrosis. As no effective anti-fibrotic therapy currently exists, the unchecked progression of fibrogenesis manifests as cardio-renal failure and early death. We have previo
Externí odkaz:
https://doaj.org/article/7dbce0f1f066420eaf5a8232a891d531
Autor:
Bharat B Mittal, Douglas E Vaughan
Publikováno v:
The Lancet Healthy Longevity. 4:e185-e186
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f700aecd3c3b1cb5438c6f6dc76e60e5
https://doi.org/10.1016/s2666-7568(23)00034-x
https://doi.org/10.1016/s2666-7568(23)00034-x